Docoh
Loading...

ADGI Adagio Therapeutics

APP
Utility
Compounds Specific to Coronavirus S Protein and Uses Thereof
13 Jan 22
The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S.
Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
Filed: 18 Aug 21
GRANT
Utility
Compounds specific to coronavirus S protein and uses thereof
11 Jan 22
The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S.
Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
Filed: 18 Aug 21
APP
Utility
Compounds Specific to Coronavirus S Protein and Uses Thereof
16 Dec 21
The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S.
Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
Filed: 18 Aug 21
GRANT
Utility
Compounds specific to coronavirus S protein and uses thereof
7 Dec 21
The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S.
Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
Filed: 9 Apr 21
APP
Utility
Compounds Specific to Coronavirus S Protein and Uses Thereof
21 Oct 21
The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S.
Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
Filed: 9 Apr 21
  • 1
Patents are sorted by USPTO publication date, most recent first